Gilead Sciences
GILD
Market cap $110B

88.40 USD

-3.71

4.03%

At close Nov 15, 4:00 PM EST

After hours

88.60

+0.20

0.23%

1 day

-4.03%

5 days

-8.30%

1 month

3.01%

3 months

18.91%

6 months

31.92%

Year to date

6.20%

1 year

17.80%

5 years

35.85%

10 years

-11.99%

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 18,000

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 25 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

31% more funds holding in top 10

Funds holding in top 10: 13 [Q2] → 17 (+4) [Q3]

17% more capital invested

Capital invested by funds: $73B [Q2] → $85.7B (+$12.7B) [Q3]

3% more call options, than puts

Call options by funds: $958M | Put options by funds: $928M

2% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 160

0% more funds holding

Funds holding: 1,642 [Q2] → 1,645 (+3) [Q3]

2.47% less ownership

Funds ownership: 84.72% [Q2] → 82.25% (-2.47%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 597 | Existing positions reduced: 670

See Fund Rankings

Research analyst outlook

25 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$70

21%

downside

Avg. target

$93

5%

upside

High target

$125

41%

upside

25 analyst ratings

13 positive

52%

12 neutral

48%

0 negative

0%

Wolfe Research Alexandria Hammond 0% 1-year accuracy 0 / 1 met price target	24%upside $110	Outperform Initiated	15 Nov 2024
Citigroup Geoff Meacham 42% 1-year accuracy 10 / 24 met price target	41%upside $125	Buy Initiated	14 Nov 2024
Truist Securities Asthika Goonewardene 38% 1-year accuracy 10 / 26 met price target	10%upside $97	Hold Maintained	8 Nov 2024
Oppenheimer Hartaj Singh 43% 1-year accuracy 12 / 28 met price target	19%upside $105	Outperform Maintained	7 Nov 2024
BMO Capital Evan Seigerman 47% 1-year accuracy 7 / 15 met price target	15%upside $102	Outperform Maintained	7 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 39 articles about GILD published over the past 30 days

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normaliz.

Zacks Investment Research

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Zacks Investment Research

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences to close Seattle office; shutdown impacts 72 employees

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.

Gilead Sciences to close Seattle office; shutdown impacts 72 employees

Gilead Prices $3.5 Billion of Senior Unsecured Notes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturin.

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lenac.

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Zacks Investment Research

GILD or VRTX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?

GILD or VRTX: Which Is the Better Value Stock Right Now?

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed agents with varied dosing frequencies and administration methods. The key findings presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024) reflect a transformative portfolio and future-looking pipeline focused on.

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

The Motley Fool

3 Spectacular High-Yield Dividend Stocks to Buy in November

High yields aren't a warning indicator with these three stocks.

3 Spectacular High-Yield Dividend Stocks to Buy in November

See News Rankings

Charts implemented using Lightweight Charts™